Allogene Therapeutics (ALLO)
NASDAQ:ALLO
Want to see ALLO full AI Analyst Report?
ALLO Stock Chart & Stats
$2.39
-$0.03(-1.28%)
At close: 4:00 PM EST
$2.39
-$0.03(-1.28%)
Day’s Range― - ―
52-Week Range$0.98 - $4.46
Previous CloseN/A
Volume1.66M
Average Volume (3M)7.13M
Market Cap
$707.57M
Enterprise Value$579.94M
Total Cash (Recent Filing)$266.89M
Total Debt (Recent Filing)$81.05M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding345,154,570
10 Day Avg. Volume6,712,597
30 Day Avg. Volume7,125,971
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.64
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$8.71Price Target Upside264.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.72
Revenue Forecast (FY)$13.85K
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayA secured cash runway into Q1 2029 materially reduces near-term financing pressure and provides funding to complete ALPHA3 enrollment, conduct interim/primary EFS analyses, and progress ALLO-329 dose escalation. This buying power supports execution of pivotal milestones over the next 2–3 years without immediate dilution risk.
Encouraging ALPHA3 Biomarker SignalsSubstantial MRD clearance and rapid ctDNA reduction are durable indicators of biological activity for cema-cel, supporting the drug's mechanism and the case to pursue EFS endpoints. If validated by planned mid‑2027/mid‑2028 EFS analyses, these signals could underpin regulatory submissions and sustained commercial adoption in first‑line consolidation.
Operational Scalability And Community FeasibilityRapid global site expansion and meaningful community-center participation indicate operational feasibility of outpatient, off‑the‑shelf CAR T delivery. This supports a structurally larger addressable market versus highly centralized autologous models and strengthens the long‑term commercial thesis around manufacturability and decentralized administration.
Bears Say
No Product Revenue And Persistent LossesThe absence of recurring product revenue and sustained multi‑period losses mean the company remains entirely development‑stage. Continued negative ROE and asset decline highlight balance sheet consumption; absent successful pivotal readouts or new financing, profitability and margin recovery timelines are highly uncertain beyond the current runway.
Preliminary Data Reliant On SurrogatesPromising MRD and ctDNA findings are surrogate markers; regulatory and commercial outcomes hinge on confirmation that these translate to event‑free survival. Given the small interim sample and the binary nature of pivotal readouts, program value remains contingent on mid‑2027 and mid‑2028 analyses, posing a structural outcome risk.
High Near-term Burn And Financing DependenceRising 2026 expense guidance and sustained negative cash flow underscore continued reliance on external capital to fund operations. Even with an extended runway, the company must access markets or partners to scale beyond pivotal milestones, exposing shareholders to dilution risk and execution dependence on successful clinical progress and financing windows.
Allogene Therapeutics News
ALLO FAQ
What was Allogene Therapeutics’s price range in the past 12 months?
Allogene Therapeutics lowest stock price was $0.98 and its highest was $4.46 in the past 12 months.
What is Allogene Therapeutics’s market cap?
Allogene Therapeutics’s market cap is $707.57M.
When is Allogene Therapeutics’s upcoming earnings report date?
Allogene Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were Allogene Therapeutics’s earnings last quarter?
Allogene Therapeutics released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.01.
Is Allogene Therapeutics overvalued?
According to Wall Street analysts Allogene Therapeutics’s price is currently Undervalued.
Does Allogene Therapeutics pay dividends?
Allogene Therapeutics does not currently pay dividends.
What is Allogene Therapeutics’s EPS estimate?
Allogene Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Allogene Therapeutics have?
Allogene Therapeutics has 345,154,570 shares outstanding.
What happened to Allogene Therapeutics’s price movement after its last earnings report?
Allogene Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -8.155%.
Which hedge fund is a major shareholder of Allogene Therapeutics?
Currently, no hedge funds are holding shares in ALLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allogene Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.71 (264.59% Upside)
$8.71 (264.59% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 135.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 3.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.76%
12-Months-Change
Fundamentals
Return on Equity
-56.45%
Trailing 12-Months
Asset Growth
-22.05%
Trailing 12-Months
Company Description
Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful early clinical progress — notably a strong MRD clearance signal and ctDNA reduction for cema-cel, favorable outpatient safety signals, encouraging early activity and tolerability for ALLO-329, operational scale-up and a strengthened balance sheet that extends runway into 2029. Major caveats include small interim sample size, the preliminary nature of surrogate biomarker results pending EFS validation, continued dose escalation and limited ALLO-329 maturity, and increased 2026 operating expense guidance. On balance, the call emphasized advancing, differentiated clinical data and execution momentum while acknowledging near-term clinical and financial uncertainties.View all ALLO earnings summariesALLO Stock 12 Month Forecast
Average Price Target
$8.71
▲(264.59% Upside)
Technical Analysis
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Tenaya Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
6.67% Insiders
8.68% Mutual Funds
23.39% Other Institutional Investors
51.94% Public Companies and
Individual Investors